TuHURA Biosciences, Inc./NV
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
HURA$1.51-9.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three months ended | |||
|---|---|---|---|
| March 31, · March 31, | |||
| 2025 · 2024 | |||
| Cash flows from Operating activities: | |||
| Net loss | $(6,664,371) | $(4,842,142) | |
| Adjustments to reconcile net loss to cash | |||
| used in operating activities: | |||
| Stock compensation expense | 1,424,736 | 334,604 | |
| Depreciation and amortization | 14,058 | 34,307 | |
| Amortization of debt discount | - | 17,383 | |
| Change in fair value of derivative liability | - | (12,092) | |
| Changes in operating assets and liabilities: | |||
| Other current assets | (29,998) | (1,408) | |
| Other noncurrent assets | 71,612 | (56,777) | |
| Accounts payable and accrued expenses | 445,541 | 691,880 | |
| Net cash flows from operating activities | (4,738,422) | (3,834,245) | |
| Cash flows from investing activities: | |||
| Deposits and advances, planned business acquisition | (1,108,375) | - | |
| Purchase of property and equipment | (42,672) | - | |
| Net cash flows from investing activities | (1,151,047) | - | |
| Cash flows from financing activities: | |||
| Cash dividend payment of preferred stock Series A | (2,089) | - | |
| Proceeds from warrants exercised | 504,211 | - | |
| Proceeds from convertible notes payable | - | 4,903,000 | |
| Payment of debt issuance costs | - | (272,297) | |
| Payment of transaction costs related to Kintara merger | (500,000) | - | |
| Payment of net liabilities assumed in reverse recapitalization with Kintara | (550,000) | - | |
| Net cash flows from financing activities | (547,878) | 4,630,703 | |
| Net change in cash and cash equivalents | (6,437,347) | 796,458 | |
| Cash and cash equivalents at the beginning of the period | 12,657,178 | 3,665,032 | |
| Cash and cash equivalents at the end of the period | $6,219,831 | $4,461,490 | |
| Supplemental non-cash activity | |||
| Due from stockholders not yet received for warrant exercises | $3,057,904 | $ | - |
| Right-of-use asset recognized in exchange for operating lease obligations | - | 318,722 | |
| Debt issuance costs not yet paid | - | 379,063 | |
| Deferred offering costs not yet paid | 13,965 | 284,867 | |
| Derivative liability associated with make-whole premium | - | 228,092 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.